-
1
-
-
80052270947
-
The epidemiology of renal cell carcinoma
-
Ljungberg, B. et al. The epidemiology of renal cell carcinoma. Eur. Urol. 60, 615-621 (2011
-
(2011)
Eur. Urol
, vol.60
, pp. 615-621
-
-
Ljungberg, B.1
-
2
-
-
84860223568
-
Annual Report to the Nation on the status of cancer 1975 2008, featuring cancers associated with excess weight and lack of sufficient physical activity
-
Eheman, C. et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 118, 2338-2366 (2012
-
(2012)
Cancer
, vol.118
, pp. 2338-2366
-
-
Eheman, C.1
-
3
-
-
13244267017
-
Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies
-
Hunt, J. D., van der Hel, O. L., McMillan, G. P., Boffetta, P. & Brennan, P. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. Int. J. Cancer 114, 101-108 (2005
-
(2005)
Int. J. Cancer
, vol.114
, pp. 101-108
-
-
Hunt, J.D.1
Van Der Hel, O.L.2
McMillan, G.P.3
Boffetta, P.4
Brennan, P.5
-
4
-
-
77953666412
-
Molecularly targeted agents for renal cell carcinoma: The next generation
-
Cowey, C. L. & Hutson, T. E. Molecularly targeted agents for renal cell carcinoma: The next generation. Clin. Adv. Hematol. Oncol. 8, 357-364 (2010
-
(2010)
Clin. Adv. Hematol. Oncol
, vol.8
, pp. 357-364
-
-
Cowey, C.L.1
Hutson, T.E.2
-
5
-
-
84861133861
-
RCDB: Renal cancer gene database
-
Ramana, J. RCDB: Renal Cancer Gene Database. BMC Res. Notes 5, 246 (2012
-
(2012)
BMC Res. Notes 5
, vol.246
-
-
Ramana, J.1
-
6
-
-
33845711356
-
Cancer incidence before and after kidney transplantation
-
Vajdic, C. M. et al. Cancer incidence before and after kidney transplantation. JAMA 296, 2823-2831 (2006
-
(2006)
JAMA
, vol.296
, pp. 2823-2831
-
-
Vajdic, C.M.1
-
7
-
-
70349498763
-
The pattern of excess cancer in dialysis and transplantation
-
Stewart, J. H. et al. The pattern of excess cancer in dialysis and transplantation. Nephrol. Dial. Transplant. 24, 3225-3231 (2009
-
(2009)
Nephrol. Dial. Transplant
, vol.24
, pp. 3225-3231
-
-
Stewart, J.H.1
-
8
-
-
77952248366
-
Epidemiology and risk factors for kidney cancer
-
Chow, W. H., Dong, L. M. & Devesa, S. S. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7, 245-257 (2010
-
(2010)
Nat. Rev. Urol
, vol.7
, pp. 245-257
-
-
Chow, W.H.1
Dong, L.M.2
Devesa, S.S.3
-
10
-
-
0029871708
-
Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine
-
Muslin, A. J., Tanner, J. W., Allen, P. M. & Shaw, A. S. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84, 889-897 (1996
-
(1996)
Cell
, vol.84
, pp. 889-897
-
-
Muslin, A.J.1
Tanner, J.W.2
Allen, P.M.3
Shaw, A.S.4
-
11
-
-
0032474838
-
A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity
-
Tzivion, G., Luo, Z. & Avruch, J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394, 88-92 (1998
-
(1998)
Nature
, vol.394
, pp. 88-92
-
-
Tzivion, G.1
Luo, Z.2
Avruch, J.3
-
12
-
-
0030584088
-
Serine phosphorylation of death agonist bad in response to survival factor results in binding to 14-3-3 not bcl-x(l
-
Zha, J., Harada, H., Yang, E., Jockel, J. & Korsmeyer, S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87, 619-628 (1996
-
(1996)
Cell
, vol.87
, pp. 619-628
-
-
Zha, J.1
Harada, H.2
Yang, E.3
Jockel, J.4
Korsmeyer, S.J.5
-
13
-
-
0033587773
-
Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins
-
Zhang, L., Chen, J. & Fu, H. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc. Natl Acad. Sci. USA 96, 8511-8515 (1999
-
(1999)
Proc. Natl Acad. Sci. USA
, vol.96
, pp. 8511-8515
-
-
Zhang, L.1
Chen, J.2
Fu, H.3
-
14
-
-
79960561810
-
14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid
-
Minamida, S. et al. 14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid. Anal. Bioanal. Chem. 401, 245-252 (2011
-
(2011)
Anal. Bioanal. Chem
, vol.401
, pp. 245-252
-
-
Minamida, S.1
-
15
-
-
72849149047
-
Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation
-
Liang, S. et al. Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis 30, 4152-4162 (2009
-
(2009)
Electrophoresis
, vol.30
, pp. 4152-4162
-
-
Liang, S.1
-
16
-
-
0032512724
-
Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury
-
Ichimura, T. et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 273, 4135-4142 (1998
-
(1998)
J. Biol. Chem
, vol.273
, pp. 4135-4142
-
-
Ichimura, T.1
-
17
-
-
1242343823
-
Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury
-
Ichimura, T. Hung, C. C., Yang, S. A., Stevens, J. L. & Bonventre, J. V. Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. 286, F552-F563 (2004
-
(2004)
Am. J. Physiol
, vol.286
-
-
Ichimura, T.1
Hung, C.C.2
Yang, S.A.3
Stevens, J.L.4
Bonventre, J.V.5
-
18
-
-
0036314217
-
Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury
-
Han, W. K. Bailly, V., Abichandani, R., Thadhani, R. & Bonventre, J. V. Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int. 62, 237-244 (2002
-
(2002)
Kidney Int
, vol.62
, pp. 237-244
-
-
Han, W.K.1
Bailly, V.2
Abichandani, R.3
Thadhani, R.4
Bonventre, J.V.5
-
19
-
-
34948814501
-
Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region
-
Zhang, Z., Humphreys, B. D. & Bonventre, J. V. Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J. Am. Soc. Nephrol. 18, 2704-2714 (2007
-
(2007)
J. Am. Soc. Nephrol
, vol.18
, pp. 2704-2714
-
-
Zhang, Z.1
Humphreys, B.D.2
Bonventre, J.V.3
-
20
-
-
24344507726
-
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma
-
Han, W. K. et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J. Am. Soc. Nephrol. 16, 1126-1134 (2005
-
(2005)
J. Am. Soc. Nephrol
, vol.16
, pp. 1126-1134
-
-
Han, W.K.1
-
21
-
-
80052945596
-
Urine Metabolomics For kidney Cancer Detection And Biomarker Discovery
-
Ganti, S. & Weiss, R. H. Urine metabolomics for kidney cancer detection and biomarker discovery. Urol. Oncol. 29, 551-557 (2011
-
(2011)
Urol. Oncol
, vol.29
, pp. 551-557
-
-
Ganti, S.1
Weiss, R.H.2
-
22
-
-
0036690151
-
Endogenous kynurenines as targets for drug discovery and development
-
Stone, T. W. & Darlington, L. G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 1, 609-620 (2002
-
(2002)
Nat. Rev. Drug Discov
, vol.1
, pp. 609-620
-
-
Stone, T.W.1
Darlington, L.G.2
-
23
-
-
16744366213
-
VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation
-
Brauch, H. et al. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 60, 1942-1948 (2000
-
(2000)
Cancer Res
, vol.60
, pp. 1942-1948
-
-
Brauch, H.1
-
24
-
-
12444279265
-
On the origin of cancer cells
-
Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956
-
(1956)
Science
, vol.123
, pp. 309-314
-
-
Warburg, O.1
-
25
-
-
67449105048
-
-
Perroud, B., Ishimaru, T., Borowsky, A. D. & Weiss, R. H. Grade-dependent proteomics characterization of kidney cancer. Mol. Cell. Proteomics 8, 971-985 (2009
-
(2009)
Grade-dependent proteomics characterization of kidney cancer. Mol. Cell. Proteomics
, vol.8
, pp. 971-985
-
-
Perroud, B.1
Ishimaru, T.2
Borowsky, A.D.3
Weiss, R.H.4
-
26
-
-
38649107388
-
Ido-expressing regulatory dendritic cells in cancer and chronic infection
-
Popov, A. & Schultze, J. L. IDO-expressing regulatory dendritic cells in cancer and chronic infection. J. Mol. Med. 86, 145-160 (2008
-
(2008)
J. Mol. Med
, vol.86
, pp. 145-160
-
-
Popov, A.1
Schultze, J.L.2
-
27
-
-
80052016154
-
IDO: More than an enzyme
-
Chen, W. IDO: More than an enzyme. Nat. Immunol. 12, 809-811 (2011
-
(2011)
Nat. Immunol
, vol.12
, pp. 809-811
-
-
Chen, W.1
-
28
-
-
76249093444
-
Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance
-
Godin-Ethier, J. et al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J. Immunol. 183, 7752-7760 (2009
-
(2009)
J. Immunol
, vol.183
, pp. 7752-7760
-
-
Godin-Ethier, J.1
-
29
-
-
77951744263
-
Urinary biomarkers for the early diagnosis of kidney cancer
-
Morrissey, J. J., London, A. N., Luo, J. & Kharasch, E. D. Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin. Proc. 85, 413-421 (2010
-
(2010)
Mayo Clin. Proc
, vol.85
, pp. 413-421
-
-
Morrissey, J.J.1
London, A.N.2
Luo, J.3
Kharasch, E.D.4
-
30
-
-
69249220223
-
Expression of aquaporin 1 in primary renal tumors: A prognostic indicator for clear-cell renal cell carcinoma
-
Huang, Y. et al. Expression of aquaporin 1 in primary renal tumors: A prognostic indicator for clear-cell renal cell carcinoma. Eur. Urol. 56, 690-698 (2009
-
(2009)
Eur. Urol
, vol.56
, pp. 690-698
-
-
Huang, Y.1
-
31
-
-
0032548878
-
Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy
-
Takenawa, J. et al. Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy. Int. J. Cancer 79, 1-7 (1998
-
(1998)
Int. J. Cancer
, vol.79
, pp. 1-7
-
-
Takenawa, J.1
-
32
-
-
13844254987
-
Gene expression analysis of renal carcinoma: Adipose differentiation- related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma
-
Yao, M. et al. Gene expression analysis of renal carcinoma: Adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol. 205, 377-387 (2005
-
(2005)
J. Pathol
, vol.205
, pp. 377-387
-
-
Yao, M.1
-
33
-
-
33846289955
-
Expression of adipose differentiation-related protein: A predictor of cancer-specific survival in clear cell renal carcinoma
-
Yao, M. et al. Expression of adipose differentiation-related protein: A predictor of cancer-specific survival in clear cell renal carcinoma. Clin. Cancer Res. 13, 152-160 (2007
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 152-160
-
-
Yao, M.1
-
34
-
-
0020376310
-
Prognostic significance of morphologic parameters in renal cell carcinoma
-
Fuhrman, S. A., Lasky, L. C. & Limas, C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 6, 655-663 (1982
-
(1982)
Am. J. Surg. Pathol
, vol.6
, pp. 655-663
-
-
Fuhrman, S.A.1
Lasky, L.C.2
Limas, C.3
-
35
-
-
0036151647
-
Renal epithelial neoplasms: The diagnostic implications of electron microscopic study in 55 cases
-
Krishnan, B. & Truong, L. D. Renal epithelial neoplasms: The diagnostic implications of electron microscopic study in 55 cases. Hum. Pathol. 33, 68-79 (2002
-
(2002)
Hum. Pathol
, vol.33
, pp. 68-79
-
-
Krishnan, B.1
Truong, L.D.2
-
36
-
-
77955158430
-
Pathway signature and cellular differentiation in clear cell renal cell carcinoma
-
Tun, H. W. et al. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS ONE 5, e10696 (2010
-
(2010)
PLoS ONE
, vol.5
-
-
Tun, H.W.1
-
37
-
-
84855447249
-
MicroRNAs: Processing, maturation, target recognition and regulatory functions
-
Shukla, G. C., Singh, J. & Barik, S. MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol. Cell. Pharmacol. 3, 83-92 (2011
-
(2011)
Mol. Cell. Pharmacol
, vol.3
, pp. 83-92
-
-
Shukla, G.C.1
Singh, J.2
Barik, S.3
-
38
-
-
77954932826
-
Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis
-
Gerin, I. et al. Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis. Am. J. Physiol. Endocrinol. Metab. 299, E198-E206 (2010
-
(2010)
Am. J. Physiol. Endocrinol. Metab
, vol.299
-
-
Gerin, I.1
-
39
-
-
81555212723
-
Cardiac insulin resistance and microRNA modulators
-
Pulakat, L., Aroor, A. R., Gul, R. & Sowers, J. R. Cardiac insulin resistance and microRNA modulators. Exp. Diabetes Res. 2012, 654904 (2012
-
(2012)
Exp. Diabetes Res
, vol.2012
, pp. 654904
-
-
Pulakat, L.1
Aroor, A.R.2
Gul, R.3
Sowers, J.R.4
-
40
-
-
38049103266
-
MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression
-
Lee, D. Y., Deng, Z., Wang, C. H. & Yang, B. B. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc. Natl Acad. Sci. USA 104, 20350-20355 (2007
-
(2007)
Proc. Natl Acad. Sci. USA
, vol.104
, pp. 20350-20355
-
-
Lee, D.Y.1
Deng, Z.2
Wang, C.H.3
Yang, B.B.4
-
41
-
-
48749122914
-
Circulating microRNAs as stable blood-based markers for cancer detection
-
Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008
-
(2008)
Proc. Natl Acad. Sci. USA
, vol.105
, pp. 10513-10518
-
-
Mitchell, P.S.1
-
42
-
-
72449180374
-
Circulating micrornas in breast cancer and healthy subjects
-
Zhu, W., Qin, W., Atasoy, U. & Sauter, E. R. Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes 2, 89 (2009
-
(2009)
BMC Res. Notes
, vol.2
, pp. 89
-
-
Zhu, W.1
Qin, W.2
Atasoy, U.3
Sauter, E.R.4
-
43
-
-
57649091633
-
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform
-
Resnick, K. E. et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112, 55-59 (2009
-
(2009)
Gynecol. Oncol
, vol.112
, pp. 55-59
-
-
Resnick, K.E.1
-
44
-
-
84858712300
-
Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma
-
Redova, M. et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Translat. Med. 10, 55 (2012
-
(2012)
J. Translat. Med
, vol.10
, pp. 55
-
-
Redova, M.1
-
45
-
-
77649259296
-
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells
-
Godlewski, J. et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 37, 620-632 (2010
-
(2010)
Mol. Cell
, vol.37
, pp. 620-632
-
-
Godlewski, J.1
-
46
-
-
84856018708
-
Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer
-
Liu, H. et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 316, 196-203 (2012
-
(2012)
Cancer Lett
, vol.316
, pp. 196-203
-
-
Liu, H.1
-
47
-
-
84864055685
-
Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients
-
Song, J. et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig. Dis. Sci. 57, 897-904 (2012
-
(2012)
Dig. Dis. Sci
, vol.57
, pp. 897-904
-
-
Song, J.1
-
48
-
-
55549134997
-
Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for emerging targeted cancer therapies
-
Belldegrun, A. S. et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for emerging targeted cancer therapies. Cancer 113, 2457-2463 (2008
-
(2008)
Cancer
, vol.113
, pp. 2457-2463
-
-
Belldegrun, A.S.1
-
49
-
-
0030795733
-
Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site
-
Muller, Y. A. et al. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl Acad. Sci. USA 94, 7192-7197 (1997
-
(1997)
Proc. Natl Acad. Sci. USA
, vol.94
, pp. 7192-7197
-
-
Muller, Y.A.1
-
50
-
-
0642306485
-
VEGF-receptor signal transduction
-
Cross, M. J., Dixelius, J., Matsumoto, T. & Claesson-Welsh, L. VEGF-receptor signal transduction. Trends Biochem. Sci. 28, 488-494 (2003
-
(2003)
Trends Biochem. Sci
, vol.28
, pp. 488-494
-
-
Cross, M.J.1
Dixelius, J.2
Matsumoto, T.3
Claesson-Welsh, L.4
-
51
-
-
51049084870
-
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors
-
Nickerson, M. L. et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 14, 4726-4734 (2008
-
(2008)
Clin. Cancer Res
, vol.14
, pp. 4726-4734
-
-
Nickerson, M.L.1
-
52
-
-
33644657042
-
Kidney cancer: Identification of novel targets for therapy
-
Weiss, R. H. & Lin, P. Y. Kidney cancer: Identification of novel targets for therapy. Kidney Int. 69, 224-232 (2006
-
(2006)
Kidney Int
, vol.69
, pp. 224-232
-
-
Weiss, R.H.1
Lin, P.Y.2
-
53
-
-
0030895147
-
Vascular endothelial growth factor expression is increased in renal cell carcinoma
-
Nicol, D. et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J. Urol. 157, 1482-1486 (1997
-
(1997)
J. Urol
, vol.157
, pp. 1482-1486
-
-
Nicol, D.1
-
54
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004
-
(2004)
Cancer Res
, vol.64
, pp. 7099-7109
-
-
Wilhelm, S.M.1
-
55
-
-
76249126867
-
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma
-
Huang, D. et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 70, 1053-1062 (2010
-
(2010)
Cancer Res
, vol.70
, pp. 1053-1062
-
-
Huang, D.1
-
56
-
-
0030856731
-
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta, L. G. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997
-
(1997)
Cancer Res
, vol.57
, pp. 4593-4599
-
-
Presta, L.G.1
-
57
-
-
57349179851
-
Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy
-
Sloan, B. & Scheinfeld, N. S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs 9, 1324-1335 (2008
-
(2008)
Curr. Opin. Investig. Drugs
, vol.9
, pp. 1324-1335
-
-
Sloan, B.1
Scheinfeld, N.S.2
-
58
-
-
79551717184
-
Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
-
Rini, B. I. et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117, 758-767 (2011
-
(2011)
Cancer
, vol.117
, pp. 758-767
-
-
Rini, B.I.1
-
59
-
-
82755183572
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (axis): A randomised phase 3 trial
-
Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378, 1931-1939 (2011
-
(2011)
Lancet
, vol.378
, pp. 1931-1939
-
-
Rini, B.I.1
-
60
-
-
67749111502
-
The lkb1-ampk pathway: Metabolism and growth control in tumour suppression
-
Shackelford, D. B. & Shaw, R. J. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9, 563-575 (2009
-
(2009)
Nat. Rev. Cancer
, vol.9
, pp. 563-575
-
-
Shackelford, D.B.1
Shaw, R.J.2
-
61
-
-
77952773418
-
VHL and HIF signalling in renal cell carcinogenesis
-
Baldewijns, M. M. et al. VHL and HIF signalling in renal cell carcinogenesis. J. Pathol. 221, 125-138 (2010
-
(2010)
J. Pathol
, vol.221
, pp. 125-138
-
-
Baldewijns, M.M.1
-
62
-
-
33845309430
-
Activation of the mTOR signaling pathway in renal clear cell carcinoma
-
Robb, V. A., Karbowniczek, M., Klein-Szanto, A. J. & Henske, E. P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J. Urol. 177, 346-352 (2007
-
(2007)
J. Urol
, vol.177
, pp. 346-352
-
-
Robb, V.A.1
Karbowniczek, M.2
Klein-Szanto, A.J.3
Henske, E.P.4
-
63
-
-
0028072991
-
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
-
Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700-9704 (1994
-
(1994)
Proc. Natl Acad. Sci. USA
, vol.91
, pp. 9700-9704
-
-
Herman, J.G.1
-
64
-
-
0036401042
-
Design and discovery of small molecules targeting raf-1 kinase
-
Lowinger, T. B., Riedl, B., Dumas, J. & Smith, R. A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharmacol. Des. 8, 2269-2278 (2002
-
(2002)
Curr. Pharmacol. Des
, vol.8
, pp. 2269-2278
-
-
Lowinger, T.B.1
Riedl, B.2
Dumas, J.3
Smith, R.A.4
-
65
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003
-
(2003)
Clin. Cancer Res
, vol.9
, pp. 327-337
-
-
Mendel, D.B.1
-
66
-
-
67651232490
-
Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib
-
Solowiej, J. et al. Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry 48, 7019-7031 (2009
-
(2009)
Biochemistry
, vol.48
, pp. 7019-7031
-
-
Solowiej, J.1
-
67
-
-
42249108682
-
Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway
-
Kent, D. et al. Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin. Cancer Res. 14, 1926-1930 (2008
-
(2008)
Clin. Cancer Res
, vol.14
, pp. 1926-1930
-
-
Kent, D.1
-
68
-
-
4544302751
-
Switching on kinases: Oncogenic activation of BRAF and the PDGFR family
-
Dibb, N. J., Dilworth, S. M. & Mol, C. D. Switching on kinases: Oncogenic activation of BRAF and the PDGFR family. Nat. Rev. Cancer 4, 718-727 (2004
-
(2004)
Nat. Rev. Cancer
, vol.4
, pp. 718-727
-
-
Dibb, N.J.1
Dilworth, S.M.2
Mol, C.D.3
-
69
-
-
80053580433
-
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models
-
Gril, B. et al. The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS ONE 6, e25625 (2011
-
(2011)
PLoS ONE
, vol.6
-
-
Gril, B.1
-
70
-
-
80655129639
-
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy
-
Inoue, H., Hwang, S. H., Wecksler, A. T., Hammock, B. D. & Weiss, R. H. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol. Ther. 12, 827-836 (2011
-
(2011)
Cancer Biol. Ther
, vol.12
, pp. 827-836
-
-
Inoue, H.1
Hwang, S.H.2
Wecksler, A.T.3
Hammock, B.D.4
Weiss, R.H.5
-
71
-
-
33845313947
-
P21 is a prognostic marker for renal cell carcinoma: Implications for novel therapeutic approaches
-
Weiss, R. H. et al. p21 is a prognostic marker for renal cell carcinoma: Implications for novel therapeutic approaches. J. Urol. 177, 63-69 (2007
-
(2007)
J. Urol
, vol.177
, pp. 63-69
-
-
Weiss, R.H.1
-
72
-
-
44649118573
-
Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53
-
Park, S. H., Park, J. Y. & Weiss, R. H. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J. Urol. 180, 352-360 (2008
-
(2008)
J. Urol
, vol.180
, pp. 352-360
-
-
Park, S.H.1
Park, J.Y.2
Weiss, R.H.3
-
73
-
-
84862882003
-
Tumor immunotherapy directed at PD-1
-
Ribas, A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366, 2517-2519 (2012
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 2517-2519
-
-
Ribas, A.1
-
74
-
-
34247241169
-
Renal tubular epithelial expression of the coinhibitory molecule b7-dc (programmed death-1 ligand
-
Zhang, J. et al. Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand). J. Nephrol. 19, 429-438 (2006
-
(2006)
J. Nephrol
, vol.19
, pp. 429-438
-
-
Zhang, J.1
-
75
-
-
33645736792
-
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
-
Thompson, R. H. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66, 3381-3385 (2006
-
(2006)
Cancer Res
, vol.66
, pp. 3381-3385
-
-
Thompson, R.H.1
-
76
-
-
34250177269
-
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
-
Thompson, R. H. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13, 1757-1761 (2007
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 1757-1761
-
-
Thompson, R.H.1
-
77
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
-
78
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
-
79
-
-
49649114804
-
Phase I Safety And Pharmacokinetic Study Of CT-011 A Humanized Antibody Interacting With PD-2011 1, in patients with advanced hematologic malignancies
-
Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051 (2008
-
(2008)
Clin. Cancer Res
, vol.14
, pp. 3044-3051
-
-
Berger, R.1
-
80
-
-
77954899030
-
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
-
Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010
-
(2010)
J. Clin. Oncol
, vol.28
, pp. 3167-3175
-
-
Brahmer, J.R.1
-
81
-
-
84880292389
-
-
US National Library Of Medicine
-
US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/record/NCT01441765 (2013
-
(2013)
Clinical Trials.Gov Online
-
-
-
82
-
-
77956760372
-
Molecular and therapeutic potential and toxicity of valproic acid
-
doi:10.1155/2010/479364
-
Chateauvieux, S., Morceau, F., Dicato, M. & Diederich, M. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. doi:10.1155/2010/479364
-
J. Biomed. Biotechnol
-
-
Chateauvieux, S.1
Morceau, F.2
Dicato, M.3
Diederich, M.4
-
83
-
-
0032142918
-
Roles of histone acetyltransferases and deacetylases in gene regulation
-
Kuo, M. H. & Allis, C. D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20, 615-626 (1998
-
(1998)
Bioessays
, vol.20
, pp. 615-626
-
-
Kuo, M.H.1
Allis, C.D.2
-
84
-
-
68949212379
-
Lysine acetylation targets protein complexes and co-regulates major cellular functions
-
Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840 (2009
-
(2009)
Science
, vol.325
, pp. 834-840
-
-
Choudhary, C.1
-
85
-
-
34248208217
-
Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity
-
Harms, K. L. & Chen, X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67, 3145-3152 (2007
-
(2007)
Cancer Res
, vol.67
, pp. 3145-3152
-
-
Harms, K.L.1
Chen, X.2
-
86
-
-
34447509697
-
Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
-
Duvic, M. & Vu, J. Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs 16, 1111-1120 (2007
-
(2007)
Expert Opin. Investig. Drugs
, vol.16
, pp. 1111-1120
-
-
Duvic, M.1
Vu, J.2
-
87
-
-
49349098483
-
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
-
Carew, J. S., Giles, F. J. & Nawrocki, S. T. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269, 7-17 (2008
-
(2008)
Cancer Lett
, vol.269
, pp. 7-17
-
-
Carew, J.S.1
Giles, F.J.2
Nawrocki, S.T.3
-
88
-
-
59349103985
-
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
-
Fritzsche, F. R. et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8, 381 (2008
-
(2008)
BMC Cancer
, vol.8
, pp. 381
-
-
Fritzsche, F.R.1
-
89
-
-
72949118694
-
The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo
-
Jones, J. et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J. Cell. Mol. Med. 13, 2376-2385 (2009
-
(2009)
J. Cell. Mol. Med
, vol.13
, pp. 2376-2385
-
-
Jones, J.1
-
90
-
-
74949089953
-
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels
-
Mahalingam, D. et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 16, 141-153 (2010
-
(2010)
Clin. Cancer Res
, vol.16
, pp. 141-153
-
-
Mahalingam, D.1
-
91
-
-
84873097735
-
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
-
Dasari, A. et al. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest. New Drugs 1, 115-125 (2012
-
(2012)
Invest. New Drugs
, vol.1
, pp. 115-125
-
-
Dasari, A.1
-
92
-
-
84856403025
-
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models
-
Shen, L. et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 7, e30815 (2012
-
(2012)
PLoS ONE
, vol.7
-
-
Shen, L.1
-
93
-
-
31344453943
-
Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention
-
Whiteside, T. L. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Sem. Cancer Biol. 16, 3-15 (2006
-
(2006)
Sem. Cancer Biol
, vol.16
, pp. 3-15
-
-
Whiteside, T.L.1
-
94
-
-
61649105802
-
CRM1-mediated nuclear export of proteins and drug resistance in cancer
-
Turner, J. G. & Sullivan, D. M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr. Med. Chem. 15, 2648-2655 (2008
-
(2008)
Curr. Med. Chem
, vol.15
, pp. 2648-2655
-
-
Turner, J.G.1
Sullivan, D.M.2
-
95
-
-
77953617671
-
An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1
-
Koyama, M. & Matsuura, Y. An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J. 29, 2002-2013 (2010
-
(2010)
EMBO J.
, vol.29
, pp. 2002-2013
-
-
Koyama, M.1
Matsuura, Y.2
-
96
-
-
77951985216
-
Examination of the expanding pathways for the regulation of p21 expression and activity
-
Jung, Y. S., Qian, Y. & Chen, X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell. Signal. 22, 1003-1012 (2010
-
(2010)
Cell. Signal
, vol.22
, pp. 1003-1012
-
-
Jung, Y.S.1
Qian, Y.2
Chen, X.3
-
97
-
-
42149140616
-
Expression of the nuclear export protein chromosomal region maintenanceexportin 1xpo1 is a prognostic factor in human ovarian cancer
-
Noske, A. et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112, 1733-1743 (2008
-
(2008)
Cancer
, vol.112
, pp. 1733-1743
-
-
Noske, A.1
-
98
-
-
62449215108
-
The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation
-
van der Watt, P. J. et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int. J. Cancer 124, 1829-1840 (2009
-
(2009)
Int. J. Cancer
, vol.124
, pp. 1829-1840
-
-
Van Der Watt, P.J.1
-
99
-
-
80053619765
-
Cbs9106 is a novel reversible oral crm1 inhibitor with crm1 degrading activity
-
Sakakibara, K. et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 14, 3922-3931 (2011
-
(2011)
Blood
, vol.14
, pp. 3922-3931
-
-
Sakakibara, K.1
-
100
-
-
79959619518
-
P53-dependent anticancer effects of leptomycin B on lung adenocarcinoma
-
Shao, C. et al. p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother. Pharmacol. 67, 1369-1380 (2011
-
(2011)
Cancer Chemother. Pharmacol
, vol.67
, pp. 1369-1380
-
-
Shao, C.1
-
101
-
-
84858005605
-
Nuclear export of proteins and drug resistance in cancer
-
Turner, J. G., Dawson, J. & Sullivan, D. M. Nuclear export of proteins and drug resistance in cancer. Biochem. Pharmacol. 83, 1021-1032 (2012
-
(2012)
Biochem. Pharmacol
, vol.83
, pp. 1021-1032
-
-
Turner, J.G.1
Dawson, J.2
Sullivan, D.M.3
-
103
-
-
84877601009
-
Crm1 blockade by selective inhibitors of nuclear export (sine) attenuates kidney cancer growth
-
doi:10.1016/j.juro.2012.10.018
-
Inoue, H. et al. CRM1 Blockade by Selective Inhibitors of Nuclear Export (SINE) attenuates Kidney Cancer Growth. J. Urol. doi:10.1016/j.juro.2012.10.018
-
J. Urol
-
-
Inoue, H.1
-
104
-
-
84880307597
-
-
Presented at the 2012 ASCO Annual Meeting
-
Inoue, H., Kauffman, M., Shacham, S., Landesman, Y. & Weiss, R. H. Evaluation of selective inhibitors of nuclear export (SINE) CRM1 inhibitors for the treatment of renal cell carcinoma (RCC). Presented at the 2012 ASCO Annual Meeting
-
Evaluation Of Selective Inhibitors Of Nuclear Export (SINE) CRM1 Inhibitors For The Treatment Of Renal Cell Carcinoma (RCC
-
-
Inoue, H.1
Kauffman, M.2
Shacham, S.3
Landesman, Y.4
Weiss, R.H.5
-
105
-
-
84861726854
-
-
ClinicalTrials.gov [online
-
US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01607892?term=NCT01607892&rank=1 (2012
-
(2012)
US National Library Of Medicine
-
-
-
106
-
-
84861726854
-
-
ClinicalTrials.gov [online
-
US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01607905?term=NCT01607905&rank=1 (2012
-
(2012)
US National Library Of Medicine
-
-
-
108
-
-
37549043546
-
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma
-
Klatte, T. et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin. Cancer Res. 13, 7388-7393 (2007
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 7388-7393
-
-
Klatte, T.1
-
109
-
-
84856246091
-
ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma
-
Carew, J. S. et al. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. PLoS ONE 7, e31120 (2012
-
(2012)
PLoS ONE
, vol.7
-
-
Carew, J.S.1
-
110
-
-
0025132245
-
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
-
Issemann, I. & Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 (1990
-
(1990)
Nature
, vol.347
, pp. 645-650
-
-
Issemann, I.1
Green, S.2
-
111
-
-
73649141006
-
Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes
-
Ribet, C. et al. Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes. Endocrinology 151, 123-133 (2010
-
(2010)
Endocrinology
, vol.151
, pp. 123-133
-
-
Ribet, C.1
-
112
-
-
33744797915
-
Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt
-
Grabacka, M., Plonka, P. M., Urbanska, K. & Reiss, K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin. Cancer Res. 12, 3028-3036 (2006
-
(2006)
Clin. Cancer Res
, vol.12
, pp. 3028-3036
-
-
Grabacka, M.1
Plonka, P.M.2
Urbanska, K.3
Reiss, K.4
-
113
-
-
36049041867
-
Analysis of PPAR alpha function in human kidney cell line using siRNA
-
Tachibana, K. et al. Analysis of PPAR alpha function in human kidney cell line using siRNA. Nucleic Acids Symp. Ser. (Oxf.) 50, 257-258 (2006
-
(2006)
Nucleic Acids Symp. Ser. (Oxf
, vol.50
, pp. 257-258
-
-
Tachibana, K.1
-
114
-
-
26044475136
-
Peroxisome proliferator-activated receptor-alpha and liver cancer: Where do we stand? J
-
Peters, J. M., Cheung, C. & Gonzalez, F. J. Peroxisome proliferator-activated receptor-alpha and liver cancer: Where do we stand? J. Mol. Med. 83, 774-785 (2005
-
(2005)
Mol. Med
, vol.83
, pp. 774-785
-
-
Peters, J.M.1
Cheung, C.2
Gonzalez, F.J.3
-
115
-
-
84863727312
-
Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis
-
Ganti, S. et al. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res. 14, 3471-3479 (2012
-
(2012)
Cancer Res
, vol.14
, pp. 3471-3479
-
-
Ganti, S.1
-
116
-
-
0036256981
-
Peroxisome proliferator-activated receptor beta expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin
-
Suchanek, K. M. May, F. J., Lee, W. J., Holman, N. A. & Roberts-Thomson, S. J. Peroxisome proliferator-activated receptor beta expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin. Int. J. Cell Biochem. Biol. 34, 1051-1058 (2002
-
(2002)
Int. J. Cell Biochem. Biol
, vol.34
, pp. 1051-1058
-
-
Suchanek, K.M.1
May, F.J.2
Lee, W.J.3
Holman, N.A.4
Roberts-Thomson, S.J.5
-
117
-
-
0036330419
-
Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231
-
Suchanek, K. M. et al. Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol. Carcinogen. 34, 165-171 (2002
-
(2002)
Mol. Carcinogen
, vol.34
, pp. 165-171
-
-
Suchanek, K.M.1
-
118
-
-
40949118437
-
Temsirolimus, an inhibitor of mammalian target of rapamycin
-
Rini, B. I. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 14, 1286-1290 (2008
-
(2008)
Clin. Cancer Res
, vol.14
, pp. 1286-1290
-
-
Rini, B.I.1
-
119
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
-
Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
-
120
-
-
84874851836
-
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma
-
doi:10.1158/1078-0432.CCR-12-2885
-
Angevin, E. et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-12-2885
-
Clin. Cancer Res
-
-
Angevin, E.1
-
121
-
-
83255162603
-
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors
-
Yap, T. A. et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 29, 4688-4695 (2011
-
(2011)
J. Clin. Oncol
, vol.29
, pp. 4688-4695
-
-
Yap, T.A.1
-
122
-
-
84859416603
-
Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm
-
Pal, S. K. et al. Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol. Cancer Ther. 11, 526-537 (2012
-
(2012)
Mol. Cancer Ther
, vol.11
, pp. 526-537
-
-
Pal, S.K.1
-
123
-
-
0242525657
-
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors
-
Dittrich, C. et al. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin. Cancer Res. 9, 5195-5204 (2003
-
(2003)
Clin. Cancer Res
, vol.9
, pp. 5195-5204
-
-
Dittrich, C.1
-
124
-
-
77950797736
-
Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates
-
Underiner, T. L., Herbertz, T. & Miknyoczki, S. J. Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. Anticancer Agents Med. Chem. 10, 7-27 (2010
-
(2010)
Anticancer Agents Med. Chem
, vol.10
, pp. 7-27
-
-
Underiner, T.L.1
Herbertz, T.2
Miknyoczki, S.J.3
-
125
-
-
84867985179
-
-
US National Library Of Medicine
-
US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01391130?term=NCT01391130&rank=1 (2012
-
(2012)
ClinicalTrials.Gov Online
-
-
-
126
-
-
84864018642
-
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
-
Tolcher, A. W. et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 30, 2348-2353 (2012
-
(2012)
J. Clin. Oncol
, vol.30
, pp. 2348-2353
-
-
Tolcher, A.W.1
-
127
-
-
84873097735
-
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
-
Dasari, A. et al. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest. New Drugs 31, 115-125 (2013
-
(2013)
Invest. New Drugs
, vol.31
, pp. 115-125
-
-
Dasari, A.1
-
128
-
-
77649171884
-
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
-
Tan, J., Cang, S., Ma, Y., Petrillo, R. L. & Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3, 5 (2010
-
(2010)
J. Hematol. Oncol. 3
, vol.5
-
-
Tan, J.1
Cang, S.2
Ma, Y.3
Petrillo, R.L.4
Liu, D.5
-
129
-
-
77649106272
-
A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma
-
Huang, H. et al. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 16, 1634-1641 (2010
-
(2010)
Clin. Cancer Res
, vol.16
, pp. 1634-1641
-
-
Huang, H.1
-
130
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 26, 2443-2454 (2012
-
(2012)
N. Engl. J. Med
, vol.26
, pp. 2443-2454
-
-
Topalian, S.L.1
-
131
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 26, 2455-2465 (2012
-
(2012)
N. Engl. J. Med
, vol.26
, pp. 2455-2465
-
-
Brahmer, J.R.1
-
132
-
-
84867985179
-
-
US National Library Of Medicine
-
US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00620594?term=NCT00620594&rank=1 (2012
-
(2012)
ClinicalTrials.Gov Online
-
-
-
133
-
-
84867985179
-
-
US National Library Of Medicine
-
US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00854152?term=NCT00854152&rank=1 (2012
-
(2012)
ClinicalTrials.Gov [Online
-
-
-
134
-
-
4644304196
-
Phase II trial of bortezomib for patients with advanced renal cell carcinoma
-
Kondagunta, G. V. et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. 22, 3720-3725 (2004
-
(2004)
J. Clin. Oncol
, vol.22
, pp. 3720-3725
-
-
Kondagunta, G.V.1
-
135
-
-
84876086360
-
-
US National Library Of Medicine
-
US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00891280?term=NCT00891280&rank=1 (2011
-
(2011)
ClinicalTrials.Gov [Online
-
-
-
136
-
-
84867985179
-
-
US National Library Of Medicine
-
US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01609556?term=NCT01609556&rank=1 (2012
-
(2012)
ClinicalTrials.Gov [Online
-
-
-
137
-
-
84867985179
-
-
US National Library Of Medicine
-
US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00369200?term=NCT00369200&rank=1 (2012
-
(2012)
ClinicalTrials.Gov [Online
-
-
|